According to the Colorectal Cancer Alliance, colorectal cancer is the second deadliest cancer in the United States. In 2025 alone, 52,900 people in the US are expected to die from colorectal cancer. Although screening efforts and lifestyle changes have helped to reduce death rates during the past few decades, substantial unmet need remains, especially for patients who’s disease was diagnosed in later stages.
An important areas of interest for new therapeutic development in colorectal cancer is cell therapy. A number of companies and academic institutions are now pursuing the development of chimeric antigen receptor T-cell (CAR-T) therapy and other such advanced treatments for colorectal cancers. In honor of National Colorectal Cancer Awareness Month, observed annually in March by the patient and clinician communities,…